e-Therapeutics PLC - Oxford, England-based computer-based drug discovery company - Files eight patent applications in the US, to protect the rights over its GalNAc-siRNA technology. The technology is used to silence any gene in liver hepatocytes.
"This second announcement of significant patent filings within three months demonstrates fast and meaningful scientific and technological progress. It also reflects our commitment to protecting the company's proprietary innovation, which forms a critical part of our strategy as we continue to make material steps in developing a computationally driven in-house pipeline of highly differentiated RNAi medicines at speed," says Chief Executive Officer Ali Mortazavi.
Current stock price: 22.24 pence
12-month change: down 12%
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
